Adequate CSF flow was determined by pretreatment indium-111-DTPA studies. Fifteen patients received a tracer (1 to 2 mCi) and therapeutic injection (10 to 20 mCi) of intra-Ommaya 131 I-3F8. 131 I-3F8 ...

Plerixafor (Mozobil, Sanofi, Cambridge, MA, USA) is a small molecule that reversibly disrupts the interaction of CXCR4 with its ligand SDF-1, allowing the release of SCs from the marrow. 12 It is ...

The written report is the final product of the Nuclear Medicine consultation. Reports must contain specific information to identify the patient, the specific procedure, indications for the examination ...